Cala Health has finalised the initial closing of an oversubscribed growth round of $50m to support the expansion of patient access to its neurostimulation therapy.

Nexus NeuroTech Ventures and Vertex Growth Fund co-led the funding round.

Cala’s existing investors, including Johnson & Johnson Innovation – JJDC, Lightstone, and others, participated in the round.

The funding comes as the company is focused on expanding clinical evidence and patient access to its neurostimulation therapy.

A recent study by CVS Health presented at the Movement Disorders Congress highlighted the therapy's substantial benefits for individuals with essential tremor (ET), including decreased healthcare costs and enhanced clinical outcomes.

The Cala kIQ System with ‘transcutaneous afferent patterned stimulation (TAPS) therapy’ offers a non-invasive alternative for action hand tremor relief in individuals suffering from essential tremors (ET) and Parkinson's disease.

Cala Health CEO Deanna Harshbarger said: "This round of funding will propel Cala's commercialisation trajectory, notably with the recent positive Medicare Coverage Determination for Cala TAPS Therapy. It allows us to broaden patient and physician awareness of this effective and innovative treatment.

"We are very excited about the strong support from both our legacy and new investors who believe in our vision and first-in-class, on-demand technology to address tremor relief."

Launched in June 2023, the Cala kIQ System works by sensing each individual’s distinct tremor signature and delivering personalised stimulation to the nerves on the wrist, which then communicates with the brain to counteract the tremor.

ET is often treated with drugs that can cause side effects such as fatigue and nausea while surgical options carry the risk of irreversible side effects.

Founded in 2014, Cala Health is a bioelectronic medicine company that focuses on transforming the standard of care for chronic disease with its wearable neuromodulation therapies.